September 25, 2008 – Fralex Therapeutics Inc. (TSX:FXI) , a medical technology company developing a non-invasive neuromodulation device, provided an update on receiving results of the interim analysis for the RELIEF pivotal study. The trial is investigating the use of Complex Neural Pulse or CNPTM therapy for the relief of chronic pain associated with fibromyalgia.The Independent Data Monitoring Committee (“DMC”) is scheduled to meet on October 2, 2008, to review data from the first 100 patients enrolled in the trial... [PDF] Fralex Therapeutics's Press Release -
